General care

Electronic growth hormone injection device gains US approval

23 November 2007

Merck Serono, a division of Swiss company Merck KGaA, has announced that its US affiliate, EMD Serono, Inc. has received US FDA approval of its easypod delivery system for the administration of Saizen, a treatment for growth hormone deficiency.

The device was designed to help patients administer a subcutaneous daily injection, reliably and in just three simple key steps. A key feature of easypod is preset dosing, which means that patients no longer have to set their dose every day. It also tracks the number of doses administered, allowing physicians to monitor patient adherence to therapy. It is intended for use with Saizen click.easy cartridges after training from a healthcare provider.

easypod is currently available in Argentina, Australia, Austria, Brazil, Canada, Colombia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, Norway, Portugal, Slovak Republic, Spain, Sweden, Switzerland, Turkey and the United Kingdom. The company says it will be available in the United States soon.

To top

Save this page on

To top